Atención al paciente oncohematológico en tiempos de COVID-19: revisión de alcance

Nascimento, Anália Andréia de Araújo; Torres, Débora Valéria de Oliveira; Silva, Anderson Felipe Moura da; Rocha, Mayane Cleisla dos Santos; Silva, Anaclécia Ferreira da; Azevedo, Isabelle Campos de

Anália Andréia de Araújo Nascimento

Universidade Federal do Rio Grande do Norte. Natal, Rio Grande do Norte, Brazil

http://orcid.org/0000-0001-7492-2735

Débora Valéria de Oliveira Torres

Universidade Federal do Rio Grande do Norte. Natal, Rio Grande do Norte, Brazil

http://orcid.org/0000-0002-7382-5922

Anderson Felipe Moura da Silva

Universidade Federal do Rio Grande do Norte. Natal, Rio Grande do Norte, Brazil

http://orcid.org/0000-0003-4677-6296

Mayane Cleisla dos Santos Rocha

Universidade Federal do Rio Grande do Norte. Natal, Rio Grande do Norte, Brazil

http://orcid.org/0000-0003-0669-9791

Anaclécia Ferreira da Silva

Universidade Federal do Rio Grande do Norte. Natal, Rio Grande do Norte, Brazil

http://orcid.org/0000-0003-2840-9046

Isabelle Campos de Azevedo Corresponding author: Isabelle Campos de Azevedo E-mail: isabellebr2511@gmail.com

Universidade Federal do Rio Grande do Norte. Natal, Rio Grande do Norte, Brazil

http://orcid.org/0000-0001-5322-7987

Corresponding author: Isabelle Campos de Azevedo E-mail: isabellebr2511@gmail.com

EDITOR IN CHIEF: Antonio José de Almeida Filho

ASSOCIATE EDITOR: Hugo Fernandes

Reference	Year/country	Study design/number of patients ^* * The number of patients was included in studies developed with humans;	General care for onco-hematological patients in times of COVID-19 ^† † Coronavirus Disease 2019; ‡ Expert opinion evidence or narrative literature review, according to the Joana Briggs Institute Manual(14);	Level of evidence
Motlagh et al.(¹⁵15 Motlagh A, Yamrali M, Azghandi S, Azadeh P, Vaezi M, Ashrafi F, et al. COVID19 Prevention & Care; A Cancer Specific Guideline. Arch Iran Med. 2020;23(4):255-264. https://doi.org/10.34172/aim.2020.07 https://doi.org/10.34172/aim.2020.07... )	2020/ Iran	Expert opinion	Telemedicine consultations; compliance with prevention practices, such as the use of face masks, hand hygiene and social distancing; minimization of clinical/outpatient visits or patient stay in health units	V^‡
Al-shamsi et al.(¹⁶16 Al-shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, et al. A practical approach to the management of cancer patients during the novel Coronavirus Disease 2019 (COVID-19) Pandemic: an international collaborative group. Oncologist. 2020;25:1-10. https://doi.org/10.1634/theoncologist.2020-0213 https://doi.org/10.1634/theoncologist.20... )	2020/ Multicenter	Literature review	Telemedicine consultations; minimization clinical/outpatient visits or patient stay in health units; educational measures on COVID-19 management ^† † Coronavirus Disease 2019; ‡ Expert opinion evidence or narrative literature review, according to the Joana Briggs Institute Manual(14);	V^‡
Mahmoudjafari et al.(¹⁷17 Mahmoudjafari Z, Alexander M, Roddy J, Shaw R, Shigle TL, Timlin C, et al. American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States. Biol Blood Marrow Transplant. 2020;26:1043-9. https://doi.org/10.1016/j.bbmt.2020.04.005 https://doi.org/10.1016/j.bbmt.2020.04.0... )	2020/ United States of America	Expert opinion	Compliance with prevention practices, such as the use of face masks, hand hygiene and social distancing	V^‡
Teodoro, Tirapelli(¹⁸18 Teodoro JL, Tirapelli B. Covid-19 e TCTH: Recomendações para a Equipe Enfermagem. SBTMO [Internet]. 2020[cited 2020 Apr 30]. Available from: https://sbtmo.org.br/kcfinder/upload/file/Enfermagem_ORIENTA%C3%87%C3%95ES%20COVID%20EM%20PACIENTES%20PRE%20E%20P%C3%93S%20TMO.pdf https://sbtmo.org.br/kcfinder/upload/fil... )	2020/ Brazil	Expert opinion	Telemedicine consultations; minimization of clinical/outpatient visits or patient stay in health units; educational measures on COVID-19 management ^† † Coronavirus Disease 2019; ‡ Expert opinion evidence or narrative literature review, according to the Joana Briggs Institute Manual(14);	V^‡
Lupo-Stanghellini et al.(¹⁹19 Lupo-Stanghellini MT, Messina C, Marktel S, Carrabba MG, Peccatori J, Corti C, et al. Following-up allogeneic transplantation recipients during the COVID-19 pandemic. Lancet Hematol. 2020;7(8). https://doi.org/10.1016/S2352-3026(20)30176-9 https://doi.org/10.1016/S2352-3026(20)30... )	2020/ Italy	Case report/ 14 patients^* * The number of patients was included in studies developed with humans;	Telemedicine consultations	IV^§ § Evidence for case report, case series or experience report, according to the Joana Briggs Institute Manual(14).
Gosain et al.(²⁰20 Gosain R, Abdou Y, Singh A, Rana N, Puzanov I, Ernstoff MS, et al. COVID-19 and Cancer: a comprehensive review. Curr Oncol Rep. 2020;22(5):53. https://doi.org/10.1007/s11912-020-00934-7 https://doi.org/10.1007/s11912-020-00934... )	2020/ United States of America	Literature review	Compliance with prevention practices, such as the use of face masks, hand hygiene and social distancing; home insulation for 14 days before conditioning	V^‡
Saleh et al.(²¹21 Saleh ASA, Sher T, Gertz MA. Multiple Myeloma in the Time of COVID-19. Acta Haematol. 2020; 143(5):410-6. https://doi.org/10.1159/000507690 https://doi.org/10.1159/000507690... )	2020/ United States of America	Literature review	Telemedicine consultations; compliance with prevention practices, such as the use of face masks, hand hygiene and social distancing; minimization of clinical/outpatient visits or patient stay in health units	V^‡
Hungria et al.(²²22 Hungria V, Garnica M, Crusoé EQ, Magalhaes Filho RJP, Martinez G, Bittencourt R, et al. Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel - ABHH monoclonal gammopathies committe. Hematol, Transfusion Cell Ther. 2020;42(3):200-5. https://doi.org/10.1016/j.htct.2020.05.001 https://doi.org/10.1016/j.htct.2020.05.0... )	2020/ Brazil	Expert opinion	Compliance with prevention practices, such as the use of face masks, hand hygiene and social distancing	V^‡
Hamerschlak(²³23 Hamerschlak N. Recomendações da SBTMO para o tratamento da leucemia mieloide aguda na era da COVID. SBTMO [Internet]. 2020[cited 2020 Apr 15. Available from: https://www.sbtmo.org.br/kcfinder/upload/file/LMA%20na%20era%20COVID_Recomenda%C3%A7%C3%B5es%20da%20SBTMO.pdf https://www.sbtmo.org.br/kcfinder/upload... )	2020/ Brazil	Expert opinion	Visit restriction	V^‡
Machado(²⁴24 Machado CM. Recomendações para manejo da COVID-19 para SBTMO [Internet]. 2020[cited 2020 Apr 16]. Available from: https://www.sbtmo.org.br/kcfinder/upload/file/Recomenda%C3%A7%C3%B5es%20SBTMO%20para%20Manejo%20da%20COVID%206%20abril%202020_por%20Clarisse%20Machado.pdf https://www.sbtmo.org.br/kcfinder/upload... )	2020/ Brazil	Expert opinion	Telemedicine consultations; compliance with prevention practices, such as the use of face masks, hand hygiene and social distancing; minimization of clinical/outpatient visits or patient stay in health units; trip avoidance, if necessary, giving preference to private vehicles; home isolation for 14 days prior to conditioning	V^‡
Ministry of Health(²⁵25 Ministério da Saúde (BR). Secretaria de Atenção Especializada à Saúde. Nota Técnica Nº 36/2020-CGSNT/DAET/SAES/MS [Internet]. Brasília: 2020 [cited 2020 Apr 23]. Available from: https://acreditacao.abhh.com.br/adm/doc/ec1db83e7f8467bebfc2a0034952a537.pdf https://acreditacao.abhh.com.br/adm/doc/... )	2020/ Brazil	Expert opinion	Telemedicine consultations; compliance with prevention practices, such as the use of face masks, hand hygiene and social distancing; minimization of clinical/outpatient visits or patient stay in health units; educational measures on COVID-19 management^† † Coronavirus Disease 2019; ‡ Expert opinion evidence or narrative literature review, according to the Joana Briggs Institute Manual(14); ; home isolation for 14 days prior to conditioning	V^‡
Perini et al.(²⁶26 Perini GF, Fischer T, Gaiolla RD, Rocha TB, Bellesso M, Teixeira LLC et al. How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. Hematology, Transfusion and Cell Therapy. 2020;42(2): 103-110. https://doi.org/10.1016/j.htct.2020.04.002 https://doi.org/10.1016/j.htct.2020.04.0... )	2020/ Brazil	Expert opinion	Telemedicine consultation; minimization of clinical/outpatient visits or patient stay in health units; educational measures on COVID-19 management	V^‡
Raza et al.(²⁷27 Raza A, Assal A, Ali AM, Jurcic JG. Rewriting the rules for care of MDS and AML patients in the time of COVID-19. Leukemia Res Rep. 2020;13. https://doi.org/10.1016/j.lrr.2020.100201 https://doi.org/10.1016/j.lrr.2020.10020... )	2020/ United States of America	Experience report	Telemedicine consultation	IV^§ § Evidence for case report, case series or experience report, according to the Joana Briggs Institute Manual(14).
Waghmare et al.(²⁸28 Waghmare A, Abidi MZ, Boeckh M, Chemaly RF, Dadwal S, Boghdadly ZE, et al. Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. Biol Blood Marrow Transplant. 2020;26(11):1983-94. Available from: https://doi.org/10.1016/j.bbmt.2020.07.027 https://doi.org/10.1016/j.bbmt.2020.07.0... )	2020/ United States of America	Expert opinion	Compliance with prevention practices, such as the use of face masks, hand hygiene and social distancing; trip avoidance, if necessary, giving preference to private vehicles; respiratory symptom screening for patients and health professionals before entering transplant units	V^‡
Ljungman et al.(²⁹29 Ljungman P, Mikulska M, Styczynski J. Coronavirus Disease COVID-19: EBMT recommendations update. EBMT [Internet]. 2020[cited 2020 Apr 07]. Available from: https://www.ebmt.org/covid-19-and-bmt https://www.ebmt.org/covid-19-and-bmt... )	2020/ Czech Republic	Expert opinion	Telemedicine consultations; compliance with prevention practices, such as the use of face masks, hand hygiene and social distancing; trip avoidance, if necessary, giving preference to private vehicles; respiratory symptom screening for patients and healthcare professionals before entering transplant units; visit restriction; staff should preferably be dedicated to a transplant unit, not alternate care for COVID-19 patients ^† † Coronavirus Disease 2019; ‡ Expert opinion evidence or narrative literature review, according to the Joana Briggs Institute Manual(14); ; home isolation for 14 days prior to conditioning	V^‡
Garnica et al.(³⁰30 Garnica M, Valentim MJ, Furtado P, Moreira MC, Bigni R, Vinhas S, et al. COVID-19 in hematology: data from a hematologic and transplant unit. Hematol Transfus Cell Ther. 2020;42(4):293-299. https://doi.org/10.1016/j.htct.2020.08.004 https://doi.org/10.1016/j.htct.2020.08.0... )	2020/ Brazil	Case series/ 47 patients^* * The number of patients was included in studies developed with humans; 54 health professionals^* * The number of patients was included in studies developed with humans;	Compliance with prevention practices, such as wearing face masks, hand hygiene and social distancing; respiratory symptom screening for patients and healthcare professionals before entering transplant units; visit restriction; staff should preferably be dedicated to a transplant unit, not alternate care for COVID-19 patients ^† † Coronavirus Disease 2019; ‡ Expert opinion evidence or narrative literature review, according to the Joana Briggs Institute Manual(14); ; ongoing training on safety, correct use of personal protective equipment, hospital, transplant and intubation flows	IV^§ § Evidence for case report, case series or experience report, according to the Joana Briggs Institute Manual(14).
Monteiro et al.(³¹31 Monteiro DE, Fialho ICTS, Passos PM, Fuly PSC. Management of coping with the risks of COVID-19 in an oncohematological outpatient clinic: an experience report. Rev Bras Enferm.2021;74(Suppl 1):e20201080. https://doi.org/10.1590/0034-7167-2020-1080 https://doi.org/10.1590/0034-7167-2020-1... )	2021/ Brazil	Experience report	Telemedicine consultations; compliance with prevention practices, such as the use of face masks, hand hygiene and social distancing; respiratory symptoms screening for patients and healthcare professionals before entering transplant units; ongoing training on safety, correct use of personal protective equipment, hospital, transplant and intubation flows	IV^§ § Evidence for case report, case series or experience report, according to the Joana Briggs Institute Manual(14).

Reference	Year/country	Study design/number of patients	Treatment of onco-hematological patients in times of COVID-19 ^† † Coronavirus Disease 2019;	Level of evidence
Motlagh et al.(¹⁵15 Motlagh A, Yamrali M, Azghandi S, Azadeh P, Vaezi M, Ashrafi F, et al. COVID19 Prevention & Care; A Cancer Specific Guideline. Arch Iran Med. 2020;23(4):255-264. https://doi.org/10.34172/aim.2020.07 https://doi.org/10.34172/aim.2020.07... )	2020/ Iran	Expert opinion	Screening for COVID-19 infection^† † Coronavirus Disease 2019; in patients before starting therapy or whenever necessary; postponement of non-urgent HSCT ^‡ ‡ Hematopoietic Stem Cell Transplantation; , definitive therapy or provisional treatment, when possible; prioritization of cancer treatment with adaptation of the therapeutic regimen	V^§ § Evidence of expert opinion or narrative review of literature, according to the Joana Briggs Institute Manual(14);
Al-shamsi et al.(¹⁶16 Al-shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, et al. A practical approach to the management of cancer patients during the novel Coronavirus Disease 2019 (COVID-19) Pandemic: an international collaborative group. Oncologist. 2020;25:1-10. https://doi.org/10.1634/theoncologist.2020-0213 https://doi.org/10.1634/theoncologist.20... )	2020/ Multicenter	Literature review	In case of infection, procedures should be postponed (at least 14 days) until patients become asymptomatic and have at least 2 consecutive negative RT-PCR tests^\|\|, with an interval of 24 hours between tests; in case of contact with person infected with COVID-19^† † Coronavirus Disease 2019; , consider incubation period of the virus (14 days) to proceed with HSCT ^‡ ‡ Hematopoietic Stem Cell Transplantation; ; assessment of postponing transplantation or adjuvant chemotherapy in cases with low risk of disease progression	V^§ § Evidence of expert opinion or narrative review of literature, according to the Joana Briggs Institute Manual(14);
Gosain et al.(²⁰20 Gosain R, Abdou Y, Singh A, Rana N, Puzanov I, Ernstoff MS, et al. COVID-19 and Cancer: a comprehensive review. Curr Oncol Rep. 2020;22(5):53. https://doi.org/10.1007/s11912-020-00934-7 https://doi.org/10.1007/s11912-020-00934... )	2020/ United States of America	Literature review	In case of infection, procedures should be postponed (minimum 14 days) until patients become asymptomatic and have at least 2 consecutive negative RT-PCR tests^\|\|, with a 24-hour interval between tests; postponement of non-urgent HSCT^‡ ‡ Hematopoietic Stem Cell Transplantation; , definitive therapy, or interim treatment when possible; in case of contact with a person infected with COVID-19^† † Coronavirus Disease 2019; , consider the virus incubation period (14 days) to proceed with HSCT^‡ ‡ Hematopoietic Stem Cell Transplantation; ; assessment of deferral of transplantation or adjuvant chemotherapy in cases with low risk of disease progression	V^§ § Evidence of expert opinion or narrative review of literature, according to the Joana Briggs Institute Manual(14);
Saleh et al.(²¹21 Saleh ASA, Sher T, Gertz MA. Multiple Myeloma in the Time of COVID-19. Acta Haematol. 2020; 143(5):410-6. https://doi.org/10.1159/000507690 https://doi.org/10.1159/000507690... )	2020/ United States of America	Literature review	Screening for COVID-19 infection^† † Coronavirus Disease 2019; in patients before starting therapy or whenever necessary; in case of infection, procedures should be postponed (at least 14 days) until patients become asymptomatic and has at least 2 consecutive negative RT-PCR tests^\|\|, with an interval of 24 hours between tests; prioritization of cancer treatment, with adaptation of the therapeutic regimen	V§
Hungria et al.(²²22 Hungria V, Garnica M, Crusoé EQ, Magalhaes Filho RJP, Martinez G, Bittencourt R, et al. Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel - ABHH monoclonal gammopathies committe. Hematol, Transfusion Cell Ther. 2020;42(3):200-5. https://doi.org/10.1016/j.htct.2020.05.001 https://doi.org/10.1016/j.htct.2020.05.0... )	2020/ Brazil	Expert opinion	Screening for COVID-19 infection in patients before starting therapy or whenever there is a need; in case of infection, procedures should be postponed (minimum 14 days) until patients become asymptomatic and have at least 2 consecutive negative RT-PCR tests^\|\|, with a 24-hour interval between tests; prioritization of cancer treatment, with adaptation of the therapeutic regimen; in case of contact with a person infected with COVID-19, consider virus incubation period (14 days) to proceed with HSCT	V^§ § Evidence of expert opinion or narrative review of literature, according to the Joana Briggs Institute Manual(14);
Hamerschlak(²³23 Hamerschlak N. Recomendações da SBTMO para o tratamento da leucemia mieloide aguda na era da COVID. SBTMO [Internet]. 2020[cited 2020 Apr 15. Available from: https://www.sbtmo.org.br/kcfinder/upload/file/LMA%20na%20era%20COVID_Recomenda%C3%A7%C3%B5es%20da%20SBTMO.pdf https://www.sbtmo.org.br/kcfinder/upload... )	2020/ Brazil	Expert opinion	Screening for COVID-19 infection^† † Coronavirus Disease 2019; in patients before starting therapy or whenever necessary; postponement of non-urgent HSCT ^‡ ‡ Hematopoietic Stem Cell Transplantation; , definitive therapy or provisional treatment, when possible; in case of contact with person infected with COVID-19^† † Coronavirus Disease 2019; , consider virus incubation period (14 days) to proceed with HSCT ^‡ ‡ Hematopoietic Stem Cell Transplantation; ; reassess the use of intensive care with high-risk complications and critical care needs	V^§ § Evidence of expert opinion or narrative review of literature, according to the Joana Briggs Institute Manual(14);
Machado(²⁴24 Machado CM. Recomendações para manejo da COVID-19 para SBTMO [Internet]. 2020[cited 2020 Apr 16]. Available from: https://www.sbtmo.org.br/kcfinder/upload/file/Recomenda%C3%A7%C3%B5es%20SBTMO%20para%20Manejo%20da%20COVID%206%20abril%202020_por%20Clarisse%20Machado.pdf https://www.sbtmo.org.br/kcfinder/upload... )	2020/ Brazil	Expert opinion	Screening for COVID-19 infection^† † Coronavirus Disease 2019; in patients before starting therapy or whenever there is a need; in case of infection, procedures should be postponed (minimum 14 days) until patients become asymptomatic and have at least 2 consecutive negative RT-PCR tests^\|\|, with a 24-hour interval between tests; in case of contact with a person infected with COVID-19^† † Coronavirus Disease 2019; , consider virus incubation period (14 days) to proceed with HSCT^‡ ‡ Hematopoietic Stem Cell Transplantation;	V^§ § Evidence of expert opinion or narrative review of literature, according to the Joana Briggs Institute Manual(14);
Ministry of Health(²⁵25 Ministério da Saúde (BR). Secretaria de Atenção Especializada à Saúde. Nota Técnica Nº 36/2020-CGSNT/DAET/SAES/MS [Internet]. Brasília: 2020 [cited 2020 Apr 23]. Available from: https://acreditacao.abhh.com.br/adm/doc/ec1db83e7f8467bebfc2a0034952a537.pdf https://acreditacao.abhh.com.br/adm/doc/... )	2020/ Brazil	Expert opinion	Screening for COVID-19 infection^† † Coronavirus Disease 2019; in patients before starting therapy or whenever there is a need; in case of infection, procedures should be postponed (minimum 14 days) until patients become asymptomatic and have at least 2 consecutive negative RT-PCR tests^\|\|, with a 24-hour interval between tests; postponement of ^‡ ‡ Hematopoietic Stem Cell Transplantation; non-urgent HSCT, definitive therapy or interim treatment, when possible; in case of contact with a person infected with COVID-19^† † Coronavirus Disease 2019; , consider the virus incubation period (14 days) to proceed with HSCT^‡ ‡ Hematopoietic Stem Cell Transplantation;	V^§ § Evidence of expert opinion or narrative review of literature, according to the Joana Briggs Institute Manual(14);
Perini et al.(²⁶26 Perini GF, Fischer T, Gaiolla RD, Rocha TB, Bellesso M, Teixeira LLC et al. How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. Hematology, Transfusion and Cell Therapy. 2020;42(2): 103-110. https://doi.org/10.1016/j.htct.2020.04.002 https://doi.org/10.1016/j.htct.2020.04.0... )	2020/ Brazil	Expert opinion	Postponement of non-urgent HSCT^‡ ‡ Hematopoietic Stem Cell Transplantation; , definitive therapy or provisional treatment, when possible; prioritization of cancer treatment, with adaptation of the therapeutic regimen; reassess the use of intensive care with high-risk complications and intensive care needs	V^§ § Evidence of expert opinion or narrative review of literature, according to the Joana Briggs Institute Manual(14);
Raza et al.(²⁷27 Raza A, Assal A, Ali AM, Jurcic JG. Rewriting the rules for care of MDS and AML patients in the time of COVID-19. Leukemia Res Rep. 2020;13. https://doi.org/10.1016/j.lrr.2020.100201 https://doi.org/10.1016/j.lrr.2020.10020... )	2020/ United States of America	Experience report	Screening for COVID-19 infection^† † Coronavirus Disease 2019; in patients before starting therapy or whenever necessary; in case of infection, procedures should be postponed (at least 14 days) until patients become asymptomatic and has at least 2 consecutive negative RT-PCR tests ^\|\|, with an interval of 24 hours between tests; prioritization of cancer treatment, with adaptation of the therapeutic regimen	IV^¶ ¶ Evidence for case report, case series or experience report, according to the Joana Briggs Institute Manual(14).
Waghmare et al.(²⁸28 Waghmare A, Abidi MZ, Boeckh M, Chemaly RF, Dadwal S, Boghdadly ZE, et al. Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. Biol Blood Marrow Transplant. 2020;26(11):1983-94. Available from: https://doi.org/10.1016/j.bbmt.2020.07.027 https://doi.org/10.1016/j.bbmt.2020.07.0... )	2020/ United States of America	Expert opinion	Screening for COVID-19 infection^† † Coronavirus Disease 2019; in patients before starting therapy or whenever there is a need; in case of infection, procedures should be postponed (minimum 14 days) until patients become asymptomatic and have at least 2 consecutive negative RT-PCR tests^\|\|, with a 24-hour interval between tests; postponement of ^‡ ‡ Hematopoietic Stem Cell Transplantation; non-urgent HSCT, definitive therapy or interim treatment, when possible	V^§ § Evidence of expert opinion or narrative review of literature, according to the Joana Briggs Institute Manual(14);
Ljungman et al.(²⁹29 Ljungman P, Mikulska M, Styczynski J. Coronavirus Disease COVID-19: EBMT recommendations update. EBMT [Internet]. 2020[cited 2020 Apr 07]. Available from: https://www.ebmt.org/covid-19-and-bmt https://www.ebmt.org/covid-19-and-bmt... )	2020/ Czech Republic	Expert opinion	Screening for COVID-19 infection^† † Coronavirus Disease 2019; in patients before starting therapy or whenever necessary; postponement of non-urgent HSCT ^‡ ‡ Hematopoietic Stem Cell Transplantation; , definitive therapy or provisional treatment, when possible	V^§ § Evidence of expert opinion or narrative review of literature, according to the Joana Briggs Institute Manual(14);
Alhalabi et al.(³²32 Alhalabi O, Iyer S, Subbiah V. Testing for COVID-19 in patients with cancer. E Clin Med. 2020;23. https://doi.org/10.1016/j.eclinm.2020.100374 https://doi.org/10.1016/j.eclinm.2020.10... )	2020/ United States of America	Expert opinion	Postponement of non-urgent HSCT^‡ ‡ Hematopoietic Stem Cell Transplantation; , definitive therapy or provisional treatment, when possible	V^§ § Evidence of expert opinion or narrative review of literature, according to the Joana Briggs Institute Manual(14);
Zhang et al.(³³33 Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4(7):1307-10. https://doi.org/10.1182/bloodadvances.2020001907 https://doi.org/10.1182/bloodadvances.20... )	2020/ China	Experience report	Experimental use of Tocilizumab	IV^¶ ¶ Evidence for case report, case series or experience report, according to the Joana Briggs Institute Manual(14).
Moujaess et al.(³⁴34 Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit Rev Oncol Hematol. 2020;150. https://doi.org/10.1016/j.critrevonc.2020.102972 https://doi.org/10.1016/j.critrevonc.202... )	2020/ Beirut	Literature review	Screening for COVID-19 infection^† † Coronavirus Disease 2019; in patients before starting therapy or whenever there is a need; in case of infection, procedures should be postponed (minimum 14 days) until patients become asymptomatic and have at least 2 consecutive negative RT-PCR tests^\|\|, with a 24-hour interval between tests; in case of contact with a person infected with COVID-19^† † Coronavirus Disease 2019; , consider virus incubation period (14 days) to proceed with HSCT^‡ ‡ Hematopoietic Stem Cell Transplantation;	V§

Reference	Year/country	Study design/number of patients	Guidelines for bone marrow donors in times of COVID-19 ^† † Coronavirus Disease 2019; ‡Expert opinion evidence or literature narrative review, according to the Joana Briggs Institute Manual(14).	Level of evidence
Waghmare et al.(²⁸28 Waghmare A, Abidi MZ, Boeckh M, Chemaly RF, Dadwal S, Boghdadly ZE, et al. Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. Biol Blood Marrow Transplant. 2020;26(11):1983-94. Available from: https://doi.org/10.1016/j.bbmt.2020.07.027 https://doi.org/10.1016/j.bbmt.2020.07.0... )	2020/ United States of America	Expert opinion	In case of close contact with a person diagnosed with COVID-19 ^† † Coronavirus Disease 2019; ‡Expert opinion evidence or literature narrative review, according to the Joana Briggs Institute Manual(14). , donors will be excluded from donation for at least 28 days	V^‡
Ljungman et al.(²⁹29 Ljungman P, Mikulska M, Styczynski J. Coronavirus Disease COVID-19: EBMT recommendations update. EBMT [Internet]. 2020[cited 2020 Apr 07]. Available from: https://www.ebmt.org/covid-19-and-bmt https://www.ebmt.org/covid-19-and-bmt... )	2020/ Czech Republic	Expert opinion	In case of close contact with a person diagnosed with COVID-19 ^† † Coronavirus Disease 2019; ‡Expert opinion evidence or literature narrative review, according to the Joana Briggs Institute Manual(14). , donors will be excluded from donation for at least 28 days; in confirming the diagnosis of COVID-19 ^† † Coronavirus Disease 2019; ‡Expert opinion evidence or literature narrative review, according to the Joana Briggs Institute Manual(14). , donors should be excluded from donation, considering releasing after three months; donors must have been asymptomatic for at least 14 (preferably 21) days prior to donation.	V^‡
Moujaess et al.(³⁴34 Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit Rev Oncol Hematol. 2020;150. https://doi.org/10.1016/j.critrevonc.2020.102972 https://doi.org/10.1016/j.critrevonc.202... )	2020/ Beirut	Literature review	In case of close contact with a person diagnosed with COVID-19, donors will be excluded from donation for at least 28 days; in confirming the diagnosis of COVID-19, donors should be excluded from donation, considering releasing after three months	V^‡

[1] Corresponding author: Isabelle Campos de Azevedo E-mail: isabellebr2511@gmail.com

Brasil

Brasil

Atención al paciente oncohematológico en tiempos de COVID-19: revisión de alcance

RESUMEN

Objetivo:

Métodos:

Resultados:

Conclusiones: